The inhibitory checkpoint molecule programmed death (PD)-1 plays a vital role in maintaining immune homeostasis upon binding to its ligands, PD-L1 and PD-L2. Several recent studies have demonstrated that soluble PD-1 (sPD-1) can block the interaction between membrane PD-1 and PD-L1 to enhance the antitumor capability of T cells. However, the affinity of natural sPD-1 binding to PD-L1 is too low to permit therapeutic applications. Here, a PD-1 variant with approximately 3000-fold and 70-fold affinity increase to bind PD-L1 and PD-L2, respectively, was generated through 
| INTRODUCTION
Cancer immunotherapy, the exploitation of one's own immune system for fighting cancer, has become a major focus in medical research and industry. Several different approaches, such as immunotherapy using tumor-infiltrating lymphocytes (TIL), 1 checkpoint blockade, 2,3 engineered T cells with chimeric antigen receptors or T-cell receptors, 4, 5 and high-affinity TCR-based biologics, 6 have been investigated and have demonstrated promising outcomes. Among these strategies, checkpoint blockade [7] [8] [9] is pivotal for determining immune status.
As a CD28/B7 family member, programmed cell death protein 1 and 1 immune receptor tyrosine-based switch motif (ITSM). [10] [11] [12] During the antigen engagement of TCR, PD-1 regulates T-cell responses by ligating its ligands, PD-L1 (also known as B7-H1 or CD274) or PD-L2 (also known as B7-DC or CD273). A cascade of signals leads to recruitment of Src homology 2-based tyrosine phosphatases (SHP-2) to the ITSM, which further induces dephosphorylation of proximal TCR signaling molecules, such as ZAP70, protein
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kinase C θ and CD3 ζ, to terminate the TCR signals. 13, 14 The signal cascade exerts a strong negative effect on production of cytokines, such as IL-2, IL-4 and IFN-γ, and on proliferation of T cells. 13, 15 Yokosuka et al 14 demonstrate that the PD-1/PD-L1 complex is functional in the immunological synapse formed at the contact site between T cells and antigen-presenting cells. The colocalization brings the complex near the TCR-peptide MHC complex to inhibit the TCR signaling pathway more efficiently during antigen recognition.
The expression patterns of PD-L1 differ from those of PD-L2.
Unlike PD-L2, which is only expressed on a few cell types such as macrophages and dendritic cells (DC), PD-L1 is widely expressed on activated T and B cells, monocytes, DC and macrophages, and at low levels on organs such as the lungs, heart, kidneys and liver. 9, 16 The PD-L1 expression can also be upregulated by stimuli such as IFN-γ, IL-2, IL-7, IL-15 and IL-21. 16, 17 The expression pattern of PD-L1 is thought to reflect the important physiological role of PD-1/PD-L1 signaling in preventing excessive T-cell activation, protecting peripheral tissue damage during an immunity to infection, and limiting autoimmunity to maintain T-cell tolerance. 15, [18] [19] [20] However, as the tumor microenvironment harbors a mass of TIL with heightened levels of PD-1, the PD-1 can be exploited by tumor cells through the upsurge of PD-L1 expression to induce cancer immune tolerance. 21 Blockade of the PD-1/PD-L1 interaction will abate the negative signaling and release T cells from the inhibitory state, thus restoring their antitumor capability. 22, 23 Several antibody drugs targeting PD-1 or PD-L1 have been approved by the US Food and Drug Administration for the treatment of malignant tumors, and many more are being tested in hundreds of clinical trials. 21, 22 Five alternative forms of PD-1, including the full-length form and the soluble form, were described in 2005. They could be produced by peripheral blood mononuclear cells (PBMC) of healthy donors, and the levels of these transcripts were increased simultaneously during the activation of PBMC with CD3 and CD28 stimulation. 24 Several studies have demonstrated that sPD-1 could block the interaction between membrane PD-1 and PD-L1, or the engagement of PD-L1/B7-1 and PD-L2/PD-1, and lead to the promotion of T-cell antitumor immunity. [25] [26] [27] These features make sPD-1 an attractive agent for blockading the PD-1/PD-L1 pathway. 28 However, the binding of natural sPD-1 to PD-L1 is weak, with a dissociation constant (K D ) of 8.2 μmol/L, 29 making sPD-1 a poor antagonist for blockading the PD-1/PD-L1 pathway. In previous studies, high-affinity sPD-1 molecules have been reported to blockade the PD-1 axis. 30, 31 However, we generated PD-1-based high-affinity PD-L1 binders with a unique mutation that played a dominant role in enhancing the binding strength. Our investigation demonstrated that the newly generated high-affinity PD-1 molecular could interact with PD-L1 on tumor cell surfaces and compete with antibodies specific to PD-L1 and PD-L2. The high-affinity PD-1 variants provide us a new way to address the problem of immune inhibition in the tumor microenvironment.
| MATERIALS AND METHODS

| Construction of human PD-1 libraries and screening for high-affinity PD-1 variants
The phage display libraries of human PD-1 (hPD-1) affinity maturation were constructed by PCR using primer mixes ( 
| Extra materials and methods
Data S1 provide the information about cell lines, gene synthesis and vector construction, phage display of PD-1 and phage ELISA, protein expression and affinity determination with surface plasmon resonance (SPR), dendritic cells preparation, flow cytometry analysis.
| RESULTS
| M13 phage displayed human PD-1 bound human PD-L1
The truncated hPD-1 gene with a C93S mutation was fused to geneIII of M13 phage to encode a protein III N-terminal fusion protein.
The fusion protein displayed on phage was examined by western blotting, and it was clearly visible as an upper band above the thick pIII protein band in a well-controlled setting ( Figure 1A ). We confirmed the hPD-1 extracellular region displayed on phage retaining hPD-L1 binding capability. As shown in Figure 1B , helper phage did not bind biotinylated hPD-L1, but PD-1-displaying phage showed clear binding. These results demonstrated that the hPD-1 displayed on M13 phage could be used for the molecular evolution of hPD-1.
| Library design and characterization
Mouse PD-1 (mPD-1) and hPD-1 share 15 identical residues among a total of 18 interface residues in contact with hPD-L1. 29 Therefore,
we used the mPD-1/hPD-L1 complex crystal structure (PDB number: 3BIK) to analyze the hPD-1/hPD-L1 interaction and selected the 18 residues for the library construction.
In addition, using the YASARA program, 34 we analyzed the potential contribution of the residues to the protein stability, especially their impacts on the hydrophobic core formation or structural integrity. As a result, six of such residues were selected, including Met70, Ala81, Pro83, Pro89, Ala125 and Gln133. Together with the 18 identified interface residues, a final list of 24 residues was generated in the hPD-1 template to construct the phage display libraries ( Figure 2A ). The 24 target residues on hPD-1 were assigned to 5
libraries (listed in Figure 2B ) to keep each library theoretical variants 
| Isolation of high-affinity PD-1 variants
Seven rounds of biopanning were carried out for the selection of high-affinity binders with the hPD-L1 captured by streptavidin-magnetic beads. Sublibraries generated from each round of biopanning were assessed for the hPD-L1 binding with polyclonal phage ELISA ( Figure 2C ). We found that PD-1 displayed on phage showed significant binding to immobilized hPD-L1 after the screening, but no binding to a negative control antigen.
Over 400 randomly picked colonies from the 7th round of biopannings were evaluated for their binding to hPD-L1, and nearly all the monoclonal phages tested were positive ( Figure 2D ). After sequence analysis, we found 19 unique sequences from the 5 libraries.
The soluble proteins of the 19 PD-1 variants were expressed as inclusion bodies in E. coli with a pET28a vector. The functional proteins were purified with anion exchange and size exclusion chromatography after refolding. We obtained 1.4-2.8 mg of proteins showing purity over 95% from 7-mg inclusion bodies.
The affinity range of binding to hPD-L1 for these variants varied greatly from micromolar to nanomolar determined by SPR ( Table 2 ).
The highest affinity PD-1 variant was a clone from library 5, named L5B7, which containing 3 mutations of G124S, K131Y and A132I (Figure 2E) . The K D of L5B7 binding to PD-L1 was 0.69 nmol/L, showing an approximately 3000-fold affinity increase. Its T 1/2 was accordingly increased from <1 seconds to approximately 500 seconds (Table 2 ).
These results indicated that the affinity-based phage display biopanning was successful in isolating high-affinity binders on a large background.
| L5B7 recognizes human PD-L1 or human PD-L2 on surfaces of tumor or dendritic cells
To assess the ability of binding to hPD-L1 expressed on cancer cells, the purified hPD-1 and L5B7 soluble proteins were used to stain We also found that L5B7 retained hPD-L2 binding capability, and the K D of L5B7 binding to hPD-L2 was 13.7 nmol/L, showing an approximately70-fold increase compared with hPD-1 ( Table 3 ). The supplementation of soluble L5B7 (1.0 × 10 −5 mol/L) could reduce over 40% mean fluorescence intensity (MFI) generated by an anti-PD-L2 Ab (M1H18) binding to hPD-L2 on mature DC ( Figure 3E ).
| The mutations at positions 124 and 132 play a key role in increasing affinity
The molecular basis of increased affinity for L5B7 was revealed by virtual mutations in silico with the help of the YASARA program and its plugin FoldX. 34, 35 As indicated in Figure 4A , when glycine at position 124 was replaced with serine, the aromatic ring of Tyr123 of hPD-L1 was rotated because of the enlarged side chain of serine compared with glycine. It caused the 2 phenol groups of Tyr68
(hPD-1) and Tyr123 (hPD-L1) to be oriented antiparallel in the complex. The π-π stacking interaction strength was increased from 2.7 to 5.8, and an additional hydrogen bond was formed between Ser124
and Tyr123. Meanwhile, we also observed the variant L4C11, where a single-site mutation from glycine to valine brought about a 28-fold affinity increase compared to hPD-1. The structural analysis showed that the site mutation increased the π-π stacking interaction strength from 2.7 to 6.0.
In the case of residue Ala132 of hPD-1, the A132I mutation caused the hPD-L1 interface hydrophobic local surface to enlarge from 628 Å 2 to 682 Å 2 , because of the larger side chain ( Figure 4B ). To analyze the structural basis of L5B7 binding to hPD-L2, we built a homology model of hPD-1/hPD-L2 using an available crystal structure of mouse PD-1/PD-L2 (PDB number: 3BP5) ( Figure 5A ), which showed high homology scores with the human counterparts.
We applied a structure-based sequence alignment of apo-hPD-1 This interaction and the residue Trp110 of hPD-L2 composed the hydrophobic core at the hPD-1/hPD-L2 interface to stabilize the complex of hPD-1 and hPD-L2 ( Figure 5D ). For A132I mutation, the hydrophobic interaction of Ile132 with Ile105 of hPD-L2 could be produced, and the mutation increased the stability of the side chain of Leu128 of hPD-1 ( Figure 5D ). Compared to the effect on the affinity binding to hPD-L1, the role of the mutations in enhancing the affinity of hPD-1 binding to hPD-L2 was very weak. This weakness might be due to the orientation discrepancy of the FG loop caused by the missing sequence in hPD-L2.
| L5B7 enhanced the proliferation and IFN-γ release of activated peripheral blood mononuclear cells
We used aCD3 and aCD28 stimulated PBMC as a T-cell activation model to examine the immune-checkpoint blocking activity of soluble hPD-1, L5B7 and anti-PD-L1 Ab respectively at the concentration of 5-μg/mL. L5B7 promoted a significantly improved PBMC proliferation from 27.1% to 55.4%, in comparison with that of hPD-1 (to 30.8%) and anti-PD-L1 Ab (to 45.3%) when PBMC were stimulated with low-dose antibodies of 15 ng/mL aCD3 and 7.5 ng/mL aCD28. Such significance could not be observed when the PBMC were stimulated with high-dose antibodies of 30 ng/mL aCD3 and 15 ng/mL aCD28. In this condition, L5B7 promoted the cell proliferation from 63.1% to 76.4%, which was similar to that of anti-PD-L1 Ab (to 74.9%) but was higher than that of hPD-1 (to 63.7%) (Figure 6A,B) . The result was consistent with the previous result that the strength of TCR signals would determine the PD-1-mediated inhibitory effects on T-cell function. 15 Enhanced cell activation was also revealed with increasing IFN-γ release of activated PBMC followed by the treatment of soluble L5B7. As shown in Figure 6C , when activated PBMC were treated with L5B7 and anti-PD-L1 Ab at the concentration of 5 μg/mL, L5B7 
| DISCUSSION
The PD-1/PD-L1 signaling pathway is crucial to the suppression of Tcell responses, and it has emerged as an important target for cancer immunotherapy. To generate a unique PD-1 axis blockade reagent, we produced soluble high-affinity PD-1 molecules for hPD-L1 binding.
The structure of the hPD-1/hPD-L1 complex (PDB number:
4ZQK) was published 36 after this work had been started, which provided a judgment for our rational phage display design. In light of the new data, we noted that all residues on hPD-1 with major contributions to hPD-1/hPD-L1 binding were selected (Asn66, Tyr68, Gly124, Ile126, Leu128, Ile134 and Glu136). Moreover, approximately 60% of residues relating to hPD-1 plasticity (from Met70 to Asp77) in the hPD-1/hPD-L1 complex were also selected.
During the current study, Maute et al 30 increase the stability and affinity to bind hPD-L1. 37 We found that the affinity of L5B7 with 3 residue mutations could attain a K D with 0.69 nmol/L for binding hPD-L1. After analyzing the complex structure, we found that the key forces in the affinity improvement were the increased strength of the π-π stacking and hydrophobic interactions in L5B7 binding to hPD-L1. It is advantageous that the affinity increase was produced from a minimum number of mutations, as introducing too many mutations can potentially make the original human protein more immunogenic. PD-L2 expression is limited to only a few cell types, it attracts less concern than PD-L1. In fact, the affinity of PD-1/PD-L2 is 3-fold to 4-fold higher than that of PD-1/PD-L1, suggesting that the binding of PD-L2 to PD-1 is better than that of PD-L1. Normally PD-L2 is mainly expressed on APC, indicating its vital role during T-cell priming, 19 whereas the signaling pathway may be exploited by tumor cells to enhance the immunosuppressive mechanism in the tumor environment. 38, 39 Increasing evidence also demonstrates that PD-L2 can be expressed on many tumor cell types, 40 and the expression is related negatively to tumor-infiltrating lymphocytes, 41 prognosis 42 and survival. 43 Targeting 47 There is no report that can indicate the relation between the affinity and irAE. Although L5B7 has a K D of 0.69 nmol/L for binding to PD-L1, which is in the range of these antibodies, we have no idea how L5B7 will behave in terms of irAE. We should pay more attention to this issue in future research.
In summary, using directed molecular evolution and highthroughput phage screening, we identified a PD-1 mutant L5B7 from a series of high-affinity PD-1 mutants that could be used to block the PD-1/PD-L1 and PD-1/PD-L2 interactions. The high-affinity PD-1 with further modification may be developed as biologics for clinic F I G U R E 6 The enhancement of proliferation and IFN-γ release of activated PBMC. A, The flow cytometry data of proliferation of activated PBMC with anti-CD3 Ab (aCD3) and anti-CD28 Ab (aCD28) in the presence or absence of soluble hPD-1, L5B7 and anti-PD-L1 Ab (5 μg/mL). PBMC were stimulated with low-dose antibodies of 15 ng/mL aCD3 and 7.5 ng/mL aCD28 or high-dose antibodies of 30 ng/mL aCD3 and 15 ng/mL aCD28. B, The statistical data of proliferating cells in (A). Error bars indicated SD (n = 3). C, ELISpot assays showing IFN-γ release of PBMC activated with 30 ng/mL aCD3 and 15 ng/mL aCD28 in the presence or absence of soluble hPD-1, L5B7 and anti-PD-L1 Ab (5 μg/mL). Error bars indicated SD (n = 3). Unpaired Student's t test, NS, P > .05; *, P < .05; **, P < .01; ***, P < .001
